St. Josephs Hospital & Medical Ctr
- Type
- Teaching hospital
- Where
- LITCHFIELD PARK, AZ
- Medicare CCN
- 030024
- Received
- $3,613,865 in 476 records, 2023 ($707,944 general, $2,905,920 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 58 | $707,944 |
| 2023 | Research payment | 418 | $2,905,920 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 418 | $2,905,920 |
| Space rental or facility fees (teaching hospital only) | 39 | $603,112 |
| Grant | 6 | $42,121 |
| Charitable Contribution | 1 | $37,445 |
| Education | 2 | $20,379 |
| Long term medical supply or device loan | 7 | $2,847 |
| Debt forgiveness | 3 | $2,037 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | ABBVIE INC. | $1,193 | Research payment | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity | 2023 |
| 2023-12-31 | ABBVIE INC. | $1,056 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 | |
| 2023-12-31 | AngioDynamics, Inc. | $833 | Long term medical supply or device loan | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2023 | |
| 2023-12-31 | AngioDynamics, Inc. | $833 | Long term medical supply or device loan | In-kind items and services | C3 WAVE SYSTEM Device, Vascular Access | 2023 | |
| 2023-12-31 | ABBVIE INC. | $799 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 | |
| 2023-12-31 | ABBVIE INC. | $698 | Research payment | In-kind items and services | A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Cl | 2023 | |
| 2023-12-31 | Stryker Corporation | $446 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $290 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, SURGICAL | 2023 | |
| 2023-12-31 | ABBVIE INC. | $231 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2023 |
| 2023-12-31 | Linvatec Corporation | $155 | Long term medical supply or device loan | In-kind items and services | VISICLEAR Device, GENERAL SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $146 | Long term medical supply or device loan | In-kind items and services | MISTRAL-AIR Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $141 | Long term medical supply or device loan | In-kind items and services | NA Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Zimmer Biomet Holdings, Inc. | $15 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | AstraZeneca UK Limited | $4 | Research payment | In-kind items and services | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo F | 2023 | |
| 2023-12-29 | Abbott Laboratories | $498 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (T | 2023 |
| 2023-12-29 | Janssen Research & Development, LLC | $370 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-12-29 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2023 |
| 2023-12-28 | NuVasive, Inc. | $26,370 | Grant | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2023 | |
| 2023-12-28 | Vitalant | $9,935 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-27 | Incyte Corporation | $6,500 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2023 | |
| 2023-12-27 | United Therapeutics Corporation | $4,200 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-27 | Janssen Research & Development, LLC | $2,394 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-12-27 | United Therapeutics Corporation | $665 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-12-22 | Sarepta Therapeutics, Inc. | $2,660 | Research payment | Cash or cash equivalent | SRP-LGMD-501-NHS | 2023 | |
| 2023-12-22 | Sarepta Therapeutics, Inc. | $1,800 | Research payment | Cash or cash equivalent | SRP-LGMD-501-NHS | 2023 | |
| 2023-12-21 | Roche Diagnostics Operations, Inc. | $20,615 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2023 |
| 2023-12-21 | Roche Diagnostics Operations, Inc. | $5,665 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2023 |
| 2023-12-21 | Regeneron Pharmaceuticals, Inc. | $2,660 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2023 |
| 2023-12-21 | Roche Diagnostics Operations, Inc. | $2,000 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2023 |
| 2023-12-21 | Abbott Laboratories | $1,995 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (T | 2023 |
| 2023-12-20 | Nevro Corp. | $2,083 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2021-01UST2D | 2023 |
| 2023-12-20 | Nevro Corp. | $250 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2018-1 US RECHARGE | 2023 |
| 2023-12-18 | Ascendis Pharma Endocrinology Inc | $6,679 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt extension | 2023 |
| 2023-12-18 | Ascendis Pharma Endocrinology Inc | $6,482 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt | 2023 |
| 2023-12-18 | Eli Lilly and Company | $10 | Research payment | In-kind items and services | A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD A | 2023 | |
| 2023-12-15 | Novocure Inc. | $1,500 | Research payment | Cash or cash equivalent | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2023 | |
| 2023-12-15 | Novocure Inc. | $1,330 | Research payment | Cash or cash equivalent | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2023 | |
| 2023-12-15 | Genentech, Inc. | $665 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-12-14 | Medtronic, Inc. | $7,731 | Research payment | In-kind items and services | STEALTHSTATION S8 PLATFORM Device, Image Guided Surgery Products | Investigator Sponsored Research | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $9,051 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $5,022 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-12 | United Therapeutics Corporation | $2,000 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-12-12 | SANOFI US SERVICES INC. | $2,000 | Research payment | Cash or cash equivalent | ENJAYMO Biological, Hematology | Cold Agglutinin Disease Real World Evidence Registry | 2023 |
| 2023-12-08 | E.R. Squibb & Sons, L.L.C. | $850 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2023 | |
| 2023-12-07 | ABBVIE INC. | $83 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2023 |
| 2023-12-06 | ABBVIE INC. | $3,130 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-12-06 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-12-06 | ABBVIE INC. | $665 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-12-05 | Cochlear Americas | $430 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-12-04 | Genentech, Inc. | $5,488 | Research payment | Cash or cash equivalent | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | 2023 | |
| 2023-12-04 | Monteris Medical Corporation | $1,750 | Research payment | Cash or cash equivalent | NeuroBlate Device, NeuroBlate | LAANTERN | 2023 |
| 2023-12-04 | Monteris Medical Corporation | $570 | Research payment | Cash or cash equivalent | NeuroBlate Device, NeuroBlate | LAANTERN | 2023 |
| 2023-12-04 | ABBVIE INC. | $200 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2023 |
| 2023-12-01 | MML US, Inc. | $12,975 | Research payment | Cash or cash equivalent | ReActiv8 Device, Pain Management | Restore | 2023 |
| 2023-12-01 | Exelixis Inc. | $9,965 | Research payment | Cash or cash equivalent | A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal C | 2023 | |
| 2023-12-01 | MML US, Inc. | $2,235 | Research payment | Cash or cash equivalent | ReActiv8 Device, Pain Management | Restore | 2023 |
| 2023-12-01 | Nevro Corp. | $1,500 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | RECHARGEIRB CLOSE106 | 2023 |
| 2023-12-01 | Nevro Corp. | $1,000 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | RECHARGECLOSEOUT106 | 2023 |
| 2023-11-30 | Tanabe Pharma America, Inc. | $2,500 | Research payment | Cash or cash equivalent | OBTAINING PATIENT BRAIN SAMPLES | 2023 | |
| 2023-11-30 | Cochlear Americas | $99 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-11-29 | Incyte Corporation | $4,750 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2023 | |
| 2023-11-27 | Vitalant | $9,935 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-11-22 | Genentech, Inc. | $8,948 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-11-22 | Amryt Pharma Holdings Ltd | $400 | Research payment | Cash or cash equivalent | MYCAPSSA Drug, Endocrinology | MACRO Registry | 2023 |
| 2023-11-21 | SANOFI US SERVICES INC. | $4,444 | Research payment | Cash or cash equivalent | ENJAYMO Biological, Hematology | Cold Agglutinin Disease Real World Evidence Registry | 2023 |
| 2023-11-20 | Abbott Laboratories | $261 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study | 2023 |
| 2023-11-20 | Roche Diagnostics Operations, Inc. | $22 | Research payment | In-kind items and services | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD006263 | 2023 |
| 2023-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25,270 | Research payment | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-214 A | 2023 |
| 2023-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,660 | Research payment | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-214 A | 2023 |
| 2023-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,000 | Research payment | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-214 A | 2023 |
| 2023-11-17 | Tanabe Pharma America, Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WIT | 2023 | |
| 2023-11-17 | Tanabe Pharma America, Inc. | $1,330 | Research payment | Cash or cash equivalent | A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WIT | 2023 | |
| 2023-11-17 | Tanabe Pharma America, Inc. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WIT | 2023 | |
| 2023-11-17 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $665 | Research payment | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-214 A | 2023 |
| 2023-11-16 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-11-15 | Intuitive Surgical, Inc. | $44,268 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2023 | |
| 2023-11-15 | Ascendis Pharma Endocrinology Inc | $19,230 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt extension | 2023 |
| 2023-11-15 | ABBVIE INC. | $2,660 | Research payment | Cash or cash equivalent | A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Cl | 2023 | |
| 2023-11-10 | Ascendis Pharma Endocrinology Inc | $6,374 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt | 2023 |
| 2023-11-10 | Genentech, Inc. | $4,340 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-11-10 | Ascendis Pharma Endocrinology Inc | $3,384 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt extension | 2023 |
| 2023-11-10 | Monteris Medical Corporation | $250 | Research payment | Cash or cash equivalent | NeuroBlate Device, NeuroBlate | LAANTERN | 2023 |
| 2023-11-09 | Genentech, Inc. | $19,090 | Research payment | Cash or cash equivalent | Phase II dose finding study in prodromal early manifest HD individuals | 2023 | |
| 2023-11-09 | Cook Research Incorporated | $600 | Research payment | Cash or cash equivalent | 14-09 Zenith p-Branch Endovascular Graft - Pivotal Study | 2023 | |
| 2023-11-09 | Tanabe Pharma America, Inc. | $340 | Research payment | Cash or cash equivalent | OBTAINING PATIENT BRAIN SAMPLES | 2023 | |
| 2023-11-07 | United Therapeutics Corporation | $28,595 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2023 |
| 2023-11-07 | United Therapeutics Corporation | $10,455 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-11-07 | SANOFI US SERVICES INC. | $100 | Research payment | Cash or cash equivalent | LUMIZYME Biological, Genetic Disease | Pompe Disease Registry | 2023 |
| 2023-11-06 | GENZYME CORPORATION | $4,220 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2023 | |
| 2023-11-06 | Cochlear Americas | $1,291 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-11-06 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-11-06 | SANOFI US SERVICES INC. | $950 | Research payment | Cash or cash equivalent | LUMIZYME Biological, Genetic Disease | Pompe Disease Registry | 2023 |
| 2023-11-06 | SANOFI US SERVICES INC. | $50 | Research payment | Cash or cash equivalent | LUMIZYME Biological, Genetic Disease | Pompe Disease Registry | 2023 |
| 2023-11-06 | SANOFI US SERVICES INC. | $50 | Research payment | Cash or cash equivalent | LUMIZYME Biological, Genetic Disease | Pompe Disease Registry | 2023 |
| 2023-11-02 | ABBVIE INC. | $4,688 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-11-01 | Sumitomo Pharma America, Inc. | $17,955 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-11-01 | KLS-Martin L.P. | $5,846 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-11-01 | Sumitomo Pharma America, Inc. | $2,000 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-10-31 | Vitalant | $9,935 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-10-29 | Nevro Corp. | $365 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | Q32023RECHARGE106 | 2023 |
| 2023-10-27 | Ascendis Pharma Endocrinology Inc | $8,276 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt extension | 2023 |
| 2023-10-27 | Ascendis Pharma Endocrinology Inc | $7,560 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt | 2023 |
| 2023-10-27 | TransMedics, Inc. | $1,710 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCS-LUN-PAS01 | 2023 |
| 2023-10-26 | Abbott Laboratories | $831 | Research payment | Cash or cash equivalent | TriClip System Device, Structural Heart | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (T | 2023 |
| 2023-10-26 | Cochlear Americas | $530 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-10-25 | Monteris Medical Corporation | $1,757 | Research payment | Cash or cash equivalent | NeuroBlate Device, NeuroBlate | LAANTERN | 2023 |
| 2023-10-25 | Hoffmann-La Roche Limited | $1,174 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-24 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-10-23 | Janssen Research & Development, LLC | $12,582 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-10-23 | Hoffmann-La Roche Limited | $6,596 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-23 | Hoffmann-La Roche Limited | $6,131 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-23 | Abbott Laboratories | $3,837 | Research payment | Cash or cash equivalent | TACTICATH Device, Electrophysiology | Abbott Atrial Fibrillation Post Approval Study | 2023 |
| 2023-10-23 | Genentech, Inc. | $1,995 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-23 | Hoffmann-La Roche Limited | $1,810 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-23 | Hoffmann-La Roche Limited | $750 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-23 | Hoffmann-La Roche Limited | $3 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-23 | Hoffmann-La Roche Limited | $3 | Research payment | Cash or cash equivalent | A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy | 2023 | |
| 2023-10-20 | Genentech, Inc. | $38 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-20 | Genentech, Inc. | $22 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-19 | Genentech, Inc. | $25,275 | Research payment | Cash or cash equivalent | Phase II dose finding study in prodromal early manifest HD individuals | 2023 | |
| 2023-10-19 | Genentech, Inc. | $5,320 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-19 | Genentech, Inc. | $2,660 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-19 | Regeneron Pharmaceuticals, Inc. | $1,282 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2023 |
| 2023-10-19 | ABBVIE INC. | $950 | Research payment | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migra | 2023 |
| 2023-10-19 | Genentech, Inc. | $665 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-18 | Intuitive Surgical, Inc. | $48,748 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2023 | |
| 2023-10-17 | Eli Lilly and Company | $25,895 | Research payment | Cash or cash equivalent | EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIEN | 2023 | |
| 2023-10-17 | Olympus Corporation of the Americas | $15,000 | Research payment | Cash or cash equivalent | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2023 | |
| 2023-10-17 | United Therapeutics Corporation | $10,331 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $8,006 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | Genentech, Inc. | $3,989 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $665 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-17 | United Therapeutics Corporation | $56 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-10-16 | Amryt Pharma Holdings Ltd | $400 | Research payment | Cash or cash equivalent | MYCAPSSA Drug, Endocrinology | MACRO Registry | 2023 |
| 2023-10-13 | Genentech, Inc. | $12,596 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-10-13 | Janssen Research & Development, LLC | $6,934 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-10-13 | Cochlear Americas | $861 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-10-10 | GENZYME CORPORATION | $4,220 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2023 | |
| 2023-10-10 | ABBVIE INC. | $3,136 | Research payment | Cash or cash equivalent | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 | |
| 2023-10-06 | TransMedics, Inc. | $10,260 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCS-LUN-PAS01 | 2023 |
| 2023-10-06 | Janssen Research & Development, LLC | $3,916 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-10-05 | Genentech, Inc. | $39,501 | Research payment | Cash or cash equivalent | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | 2023 | |
| 2023-10-05 | Novocure Inc. | $5,320 | Research payment | Cash or cash equivalent | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2023 | |
| 2023-10-05 | ABBVIE INC. | $2,926 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-10-05 | ABBVIE INC. | $2,261 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2023 |
| 2023-10-05 | ABBVIE INC. | $33 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | 2023 |
| 2023-10-04 | Baxter Healthcare | $45,716 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SEPRAFILM Device, Surgical Care | 2023 | |
| 2023-10-04 | Galvanize Therapeutics, Inc | $13,627 | Research payment | Cash or cash equivalent | RHEOX Device, PULSED ELECTRIC FIELD | CS006 RheOx Pivotal | 2023 |
| 2023-10-04 | ABBVIE INC. | $3,845 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | 2023 |
| 2023-10-03 | Nevro Corp. | $293 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2021-01UST2D | 2023 |
| 2023-10-03 | Nevro Corp. | $220 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2021-01UST2D | 2023 |
| 2023-10-03 | Nevro Corp. | $73 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2021-01UST2D | 2023 |
| 2023-10-03 | Nevro Corp. | $73 | Research payment | Cash or cash equivalent | Nevro Device, Spinal Cord Stimulator | CA2021-01UST2D | 2023 |
| 2023-09-29 | Novocure Inc. | $500 | Research payment | Cash or cash equivalent | EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b | 2023 | |
| 2023-09-28 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | PORTICO Device, Structural Heart | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO-IDE) | 2023 |
| 2023-09-28 | TransMedics, Inc. | $300 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCS-LUN-PAS01 | 2023 |
| 2023-09-27 | Vitalant | $9,935 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-09-26 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2023 | |
| 2023-09-26 | Cochlear Americas | $869 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-09-26 | Abbott Laboratories | $332 | Research payment | Cash or cash equivalent | TriClip System Device, Structural Heart | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (T | 2023 |
| 2023-09-21 | Genentech, Inc. | $3,325 | Research payment | Cash or cash equivalent | PostGraduate Roll Over Study | 2023 | |
| 2023-09-21 | Genentech, Inc. | $2,080 | Research payment | Cash or cash equivalent | Gantenerumab in Early AD | 2023 | |
| 2023-09-19 | United Therapeutics Corporation | $2,660 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-19 | Novo Nordisk Inc | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Ozempic Drug, Diabetes | 2023 | |
| 2023-09-19 | United Therapeutics Corporation | $56 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-18 | Janssen Research & Development, LLC | $180 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-09-13 | ACUMED LLC | $7,570 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OsteoMed Device, Craniomaxillofacial | 2023 | |
| 2023-09-13 | Cochlear Americas | $430 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-09-12 | Abbott Laboratories | $9,500 | Research payment | Cash or cash equivalent | MITRACLIP Device, Vascular | Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients with PrImary Mitral Regurgitation Who Are Cand | 2023 |
| 2023-09-12 | Exelixis Inc. | $2,046 | Research payment | Cash or cash equivalent | A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal C | 2023 | |
| 2023-09-12 | Exelixis Inc. | $1,995 | Research payment | Cash or cash equivalent | A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal C | 2023 | |
| 2023-09-12 | Exelixis Inc. | $1,729 | Research payment | Cash or cash equivalent | A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal C | 2023 | |
| 2023-09-12 | Genentech, Inc. | $2 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-11 | Exelixis Inc. | $21,480 | Research payment | Cash or cash equivalent | A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal C | 2023 | |
| 2023-09-11 | Janssen Research & Development, LLC | $3,853 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ6 | 2023 | |
| 2023-09-11 | Eli Lilly and Company | $1 | Research payment | In-kind items and services | POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULV | 2023 | |
| 2023-09-08 | Intuitive Surgical, Inc. | $30,432 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2023 | |
| 2023-09-08 | Intuitive Surgical, Inc. | $14,142 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2023 | |
| 2023-09-08 | Genentech, Inc. | $4,926 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $4,724 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | GENZYME CORPORATION | $4,220 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2023 | |
| 2023-09-08 | Genentech, Inc. | $1,290 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $665 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $258 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $75 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $58 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $40 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-08 | Genentech, Inc. | $31 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-09-07 | Ascendis Pharma Endocrinology Inc | $4,501 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt | 2023 |
| 2023-09-07 | Ascendis Pharma Endocrinology Inc | $1,646 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | foresiGHt extension | 2023 |
| 2023-09-07 | Cook Research Incorporated | $1,500 | Research payment | Cash or cash equivalent | ZENITH SPIRAL-Z Device, Aortic Intervention | 14-09 Zenith p-Branch Endovascular Graft - Pivotal Study | 2023 |
| 2023-09-07 | Abbott Laboratories | $997 | Research payment | Cash or cash equivalent | TriClip System Device, Structural Heart | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (T | 2023 |
| 2023-09-06 | United Therapeutics Corporation | $13,857 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-06 | United Therapeutics Corporation | $4,798 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2023 |
| 2023-09-06 | Cochlear Americas | $23 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-09-05 | Cochlear Americas | $476 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-09-05 | Cochlear Americas | $172 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-09-05 | Cochlear Americas | $142 | Research payment | Cash or cash equivalent | OSIA OSI300 IMPLANT Device, Implantable hearing solution | Osia 2 System in a pediatric expansion study | 2023 |
| 2023-08-31 | QIAGEN, LLC | $1,938 | Debt forgiveness | Cash or cash equivalent | 2023 |
The latest 200 records of 476.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Litchfield Park, AZ, county Maricopa County, AZ, state Arizona; placed by its city name.
| Measure | Place (city or town) Litchfield Park, AZ | County Maricopa County, AZ | State Arizona |
|---|---|---|---|
| Population B01003 | 6,916 | 4,559,748 | 7,378,838 |
| Population, 2020 census P1 | 6,847 | 4,420,568 | 7,151,502 |
| Median age B01002 | 45.0 | 37.6 | 39.0 |
| Under 18 B01001 | 21.9% | 22.5% | 21.6% |
| 65 and over B01001 | 19.7% | 16.3% | 18.9% |
| Households B11001 | 2,660 | 1,730,696 | 2,856,081 |
| Foreign born B05002 | 13.2% | 14.5% | 13.0% |
| Median household income B19013 | $126,250 | $89,300 | $79,964 |
| Median family income B19113 | $135,816 | $105,249 | $95,980 |
| Per capita income B19301 | $56,340 | $46,183 | $42,503 |
| Poverty rate B17001 | 3.9% | 11.0% | 12.5% |
| Unemployment rate B23025 | 3.4% | 4.5% | 5.1% |
| Civilian labor force B23025 | 3,166 | 2,373,071 | 3,598,840 |
| Mean commute (minutes) B08013 | 25.9 | 26.0 | 25.4 |
| Bachelor's degree or higher B15003 | 45.0% | 36.7% | 33.3% |
| Housing units B25001 | 2,868 | 1,884,334 | 3,192,839 |
| Owner-occupied B25003 | 84.8% | 65.2% | 67.4% |
| Renters B25003 | 15.2% | 34.8% | 32.6% |
| Median home value B25077 | $577,000 | $452,800 | $394,500 |
| Median gross rent B25064 | $1,922 | $1,708 | $1,543 |
| White, not Hispanic B03002 | 61.7% | 52.5% | 52.6% |
| Black B03002 | 1.8% | 5.4% | 4.4% |
| Hispanic or Latino B03002 | 24.8% | 31.2% | 31.4% |
| Asian B03002 | 4.9% | 4.5% | 3.5% |
| American Indian and Alaska Native B03002 | 0.3% | 1.3% | 3.2% |
Economy now FRED unemployment 4.9% in Sep 2026 (4.4% a year earlier); per capita personal income $68,373 in 2025, up 31% in five years (+5.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Litchfield Park, AZ.
Comments